Enzymatica AB: Enzymatica's rights issue is secured up to 100 percent
November 02 2018 - 3:00AM
Press release
November 2, 2018
Enzymatica's rights issue is
secured up to 100 percent
Enzymatica announced on October
18, 2018 that the Board of Directors has decided to carry out a
rights issue of a maximum of SEK 98.7 million with preferential
rights for existing shareholders, providing approval by the
Extraordinary General Meeting (EGM) on November 5, 2018. The Board
of Directors has entered into an agreement with some of the
company's existing shareholders, board members and management team
of subscription commitments and underwriting agreements for a total
amount of SEK 98.7 million, corresponding to 100 percent of the
rights Issue.
In connection with the rights Issue, Enzymatica
has received subscription commitments from a number of existing
shareholders, including members in the Board of Directors and the
management team. Total subscription commitments amount to SEK 28.2
million, corresponding to 28.6 percent of the rights Issue. In
addition, the company has entered into underwriting agreements with
the board member Mats K Andersson, through company, and two major
shareholders, amounting to SEK 70.5 million, corresponding to 71.4
percent of the rights Issue. The compensation for underwriting
agreements amounts to 7 percent of the underwriting amount. Hence,
the rights issue is secured up to SEK 98.7 million through
subscription and underwriting commitments, corresponding to 100
percent of the rights Issue.
Adviser
Erik Penser Bank AB is Enzymatica's financial
adviser in connection with the rights issue. Mannheimer Swartling
is the company's legal adviser.
The information in this press release is
information that Enzymatica is obliged to make public pursuant to
the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
below, at 09.00 CET on November 2, 2018.
For more information, please
contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708 86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and
sells medical devices for infection-related diseases. The products
are based on a barrier technology that includes marine enzymes. The
company's first product is ColdZyme® Mouth Spray, which can prevent
colds and reduce the duration of disease. The product has been
launched in about ten markets. The strategy is to continue to grow
by strengthening the company's position in existing markets and
expanding into new geographic markets through established partners.
The company has its headquarters in Lund and is listed on Nasdaq
First North. For more information,
visit: www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser
Bank.För mer information, kontakta:
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Oct 2024 to Nov 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Nov 2023 to Nov 2024
